Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin
- R. Garzon, M. Garofalo, B. Falini
- BiologyProceedings of the National Academy of Sciences
- 11 March 2008
A unique miRNA signature is identified that distinguishes NPMc+ mutated from the cytoplasmic-negative (NPM1 unmutated) cases and includes the up-regulation of miR-10a, miR -10b, several let-7 and miR –29 family members and support a role for miRNAs in the regulation of HOX genes in this leukemia subtype.
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome
- J. Griffin, J. Leung, Rebecca J Bruner, M. Caligiuri, R. Briesewitz
- BiologyProceedings of the National Academy of Sciences…
- 13 June 2003
A genetic rearrangement in the eosinophilic cell line EOL-1 is identified that results in the expression of a fusion protein comprising an N-terminal region encoded by a gene of unknown function with the GenBank accession number NM_030917 and a C-Terminal region derived from the intracellular domain of the platelet-derived growth factor receptor α (PDGFRα).
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.
Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.
Novel mutations in c-CBL and CBL-b have been identified in human AML and may represent potential targets for novel therapeutics.
Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
CDK4/6 can be a therapeutic target in Flt3 ITD AML but also in primary Flt 3 wt AML, and acquired resistance to CDK 4/6 inhibition can arise through activation CDK2.
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
It is shown here that PADs (eg, FTY720) represent suitable therapeutic alternatives for Jak2(V617F) MPNs, and that PP2A is inactive in polycythemia vera (PV) and other myeloproliferative neoplasms characterized by the expression of the transforming Jak2 (V617f) oncogene.
Sp 1 / NF k B / HDAC / miR-29 b Regulatory Network in KIT-Driven Myeloid Leukemia
This work aims to provide a scaffolding for a scalable, scalable, and scalable approach to provide real-time information about the immune system’s response to chemotherapy-related adverse events.
Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides.
The results demonstrate the feasibility of developing cyclic peptides for the inhibition of intracellular protein-protein interactions and of direct Ras inhibitors as a novel class of anticancer agents.
The role of the I domain in ligand binding of the human integrin alpha 1 beta 1.
- A. Kern, R. Briesewitz, I. Bank, E. Marcantonio
- BiologyThe Journal of biological chemistry
- 9 September 1994
Analysis of potential ligand binding domains within the human integrin alpha 1 subunit suggests a central role for the I domain in ligand recognition for all integrinalpha subunits containing this domain.